INmune Bio (INMB) Plunges 15.13% Amid Capital Raise

INmune Bio (INMB) experienced a significant decline, dropping 15.13% over the past two days, with a cumulative loss of 27.68%. The share price reached its highest level since May 2024 today, with an intraday gain of 85.35%. However, it also fell to its lowest level since January 2025, with an intraday decline of 20.22%.

The impact of INMB stock price reaching a new high on future price movements appears to be positive, as evidenced by the significant surge in stock price following the announcement of the new high.

Short-Term Performance:

- 1 Week: The stock experienced a monumental surge of +44.59% on the day the new high was reached. This indicates a strong immediate reaction from the market, suggesting that the news of the new high has significant positive implications for the stock.

- 1 Month: The 6-month gain was +91.39%, and the year-to-date gain was +93.41%. These substantial gains in the short term following the new high suggest that the positive momentum continues.

Medium-Term Performance:

- 3 Months: The 3-month performance is a critical indicator of sustained momentum. Given the ongoing positive news and the market's enthusiasm, it is reasonable to expect that the stock would continue to perform well, potentially flattening or slightly decreasing due to market corrections but maintaining a high overall level.

Long-Term Performance: The long-term performance would depend on the company's continued progress in clinical trials, regulatory approvals, and market conditions. However, the strong recent performance and the market's response to the new high suggest that INmune Bio could continue to be a strong player in the biotech sector.

In conclusion, reaching a new high stock price tends to amplify the stock's positive momentum over the short term, with the effect diminishing slightly over the medium term but remaining positive overall in the short three months. The key factors influencing this are the company's strong fundamentals, the excitement surrounding upcoming Alzheimer's drug trial data, and the broader market's interest in INmune Bio's innovative work in neurodegenerative diseases.

INmune Bio recently announced a $19 million registered direct offering on June 27, 2025. This strategic move aims to advance the company's inflammation and immunology pipeline, which could have a significant impact on its stock price. The capital raise is seen as a pivotal development for INmune Bio, as it provides the necessary funds to further its research and development efforts.

In addition to the capital raise, INmune Bio is set to announce top-line results from a conference call on June 30, 2025. This announcement is expected to provide investors with crucial insights into the company's progress and future prospects, potentially influencing stock performance. The upcoming results could either bolster investor confidence or raise concerns, depending on the outcomes presented.